A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Carcinoma Non-small-cell Lung
- Colorectal Neoplasms
- Squamous Cell Carcinoma of the Head and Neck
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This Phase 1/2, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/ recommended phase 2 dose (MTD/RP2D) of MVC-101. Dose escalation will occur in a 1+3 and then 3+3 design in patients with advanced solid tumors. Once the MTD/RP2D is determined, a Cohort...
This Phase 1/2, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/ recommended phase 2 dose (MTD/RP2D) of MVC-101. Dose escalation will occur in a 1+3 and then 3+3 design in patients with advanced solid tumors. Once the MTD/RP2D is determined, a Cohort Expansion Phase will be enrolled to further characterize safety and initial anti-tumor activity in patients with HNSCC, CRC or NSCLC.
Tracking Information
- NCT #
- NCT04844073
- Collaborators
- Not Provided
- Investigators
- Study Chair: Daniela Buglio, MD, PhD Maverick Therapeutics